- Oversaw marketing & sales, new business development, e-commerce, regulatory, logistics and distribution operations- Restructured marketing & sales team to maximize cross functional collaboration, accountability and delivery of the business through enhanced commercial governance and transparency across the organization- Improved processes for speedy regulatory compliance- Streamlined logistics and distribution functions- Employed digital and multichannel strategies for achieving product differentiation and customer loyalty

Reported to the MDLed a team of 300+; Breast Cancer, Women and Child Health - Delivered divisional P&L through achieving revenue targets US$ 44 M (est. >20% growth over target in 2020) and managing operating expenses (est. +US$100K savings in 2021) by redefining marketing strategy and aligning field force structure and priorities- Leveraged clinical research as an important marketing tool by creating a Health Research Advisory Board (HRab) in collaboration with leading physicians/institutions of the country. The basic objective of (HRab) was helping poorly funded government hospitals in establishing a basic clinical research ecosystem. The idea turned out to be an instant hit, and helped the team in developing close connections with the KOLs and the major institutes- Oversaw employment of market research into winning market strategies that drove both brand and corporate priorities- Managed OpEx, ensured cost savings, improved margins- Led sales team through significant corporate restructuring initiatives including Sales Force OptimizationAchievements As Director Commercial- Launched Hertraz (the 1st FDA approved biosimilar of Trastuzumab) in Pakistan, generated revenue of US$3 M in 2nd year, captured 36% of the market - established Hertraz as brand of choice in leading oncology institutions - Secured Pakistan Bait-ul-Maal business of value US$ 1.5 M (a Govt. of Pakistan funded program for provision of free of cost treatment to deserving population suffering from debilitating diseases (including Cancer)- Invited leading oncologist, Dr. Paul Cornes (from Bristol, UK) for a series of lectures on biosimilars, which provided a solid platform in establishing Hertraz as a treatment of choice in HER2-positive breast cancer cases

- Handled business of worth US$ 25 M of portfolios related to women and child health - Directing marketing & sales functions, with budget/P&L responsibility - Oversaw market research, competitor intelligence, sales & distribution management and budgeting & forecasting functions - Engaged key opinion leaders in a variety of academic and skill development activities, which paved the way for dependable business patronization - Ensured a thriving and competitive environment through utilization of empowerment and exposing core team to high quality trainings Achievements As Director Marketing & Sales- Increased the Paeds and Gynae franchise from US$18 M to US$25 M in ~2 years with over 24% growth in 2018 (highest in five years) - Achieved #1TRx in-class share for Ceclor and Osnate-D in 2018 - was awarded ‘most impactful campaign’ on Ceclor in 2018 (collaborated with Pakistan Pediatric Society to reach over 5,000 doctors)

Assigned to managing a US$ 20M diversified product portfolio (comprising of infant and adult nutrition range and medical devices (in addition to the responsibility of supervising international business)- Delivered anticipated sales and profitability performance in conjunction with proficient distribution support - Engaged key opinion leaders in a variety of academic and skill development activities, which paved the way for dependable business patronization - Laid a solid footing for the designated portfolios by building close relations with KOLs and professional forums like Pakistan Pediatric Society, Pakistan Endocrine Society, etc., which helped tremendously in earning important mileage both in prescriptions as well as in establishing a positive corporate imageAchievements As Director Marketing & Sales- Launched & led Lactalis International’s infant and adult nutrition portfolio under the brand name Celia in Pakistan - Managed the largest specialized infant nutrition range (comprising of Lactose Free, Low Lactose, Digest, Anti-Regurgitation, Colic and EHF)- Sold around 145,000 tins (of 400g each; all SKUs combine) in yr-1 whereas 281,000 tins in yr-2; achieved market share of over 1% & growth of 57% over year-1- Managed the largest insulin delivery portfolio in Pakistan; Insulin syringes & PNs (under licensing agreement from Becton Dickinson, drove 20% growth in ‘15-‘16- In medical equipment category represented Omron (BP Monitors, Nebulizers, Digital Thermometers) and outperformed competitors by executing strong and consistent marketing campaigns directed at consumers promoting health and well-being and by building partnerships with channel members

Headed overseas business operation worth US$ 20 M having operations in Sri Lanka, Myanmar, Cambodia, Vietnam, Philippines & Kenya- Managed commercial operations, implemented sales & marketing initiatives & identified potential marketsAchievements As Senior Marketing Manager- Initiated ‘Model Pharmacy Project’ for small hospitals and retail pharmacies, aimed at training pharmacy owners to run pharmacies on professional and profitable terms

- Managed a US$ 15 M product portfolio (cardiology and neurology) through leading a team of result driven professionals- Played a pivotal role in using Clinical Research Methodology Workshops (aimed at providing practical knowledge to clinicians interested in exploring different areas of medical research like medical writing, research protocols & study designs, application of appropriate statistical techniques, etc.) as an important marketing toolAchievements As Marketing Manager- Strengthened company’s operation by establishing four business units, thereby ensuring a focus and dedicated approach, which resulted in exhibiting 50% plus growth in sales and a ‘top 35 pharma company’ status- Developed a strategic plan for grabbing potential opportunities in emerging biotechnology and pharmaceutical markets

Successfully managed newly incepted cardio-metabolic business unit having a value of US$ 8 M in achieving the business objectives

Handled a portfolio of value US$ 5 M of cardio-metabolic range